Analysis of Outcomes in Patients with HeartMate 3 with and Without Right Ventricular Assist Device Support
ESC Heart Failure · 2025
DOI: 10.1002/ehf2.15353 ↗Kurz gefasst
Fachartikel in der Zeitschrift ESC Heart Failure, 2025. Verfasst von Vinh Q Chau und 12 weiteren Autor:innen. Beteiligte Einrichtung: Advocate Heart Institute, Advocate Christ Medical Center, Oak Lawn, Illinois, USA. Hauptthemen laut MEDLINE: Heart-Assist Devices, Heart Failure, Heart Ventricles. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Aims
Following HeartMate 3 (HM3) LVAD implantation, acute right heart failure necessitating temporary right ventricular assist device (tRVAD) support has not been extensively described. We examined clinical outcomes in patients with HM3 LVAD stratified by the need for tRVAD support. Methods and results This was a single-centre, retrospective study of patients who underwent primary HM3 implantation from 2018 to 2022. Patients were placed on tRVAD (concomitant or delayed) support due to clinical deterioration. The primary outcome was 1-year all-cause mortality following HM3 implantation using competing risk analysis with heart transplantation acting as the competing event. A matched cohort analysis was also performed to evaluate the primary outcome of patients with and without tRVAD support. Secondary outcomes included an analysis of risk of LVAD-related adverse events stratified by the presence of tRVAD. Of the 192 patients (median age 60 [49–68] years, 74% male, 37% white), 51 (26%) required tRVAD support. Compared with those with HM3 alone, the tRVAD group had a higher percentage of INTERMACS profile 1 or 2 (49% vs. 27%, P = 0.0005) and had higher rates of pre-operative VA-ECMO (28% vs. 5%, P < 0.0001). The tRVAD group had a higher 1-year all-cause mortality (33% vs. 3%, adjusted HR [95%CI]: 32.4 [9.51–110], P < 0.0001) compared with the HM3 alone group. In-hospital mortality for patients with tRVAD was 26% compared with 1% in patients with HM3 alone (P < 0.0001). In the matched cohort analysis, significantly higher risk of both stroke (HR [95% CI]: 5.75 [1.55–21.3], P = 0.009) and dialysis (HR [95% CI]: 13.4 (3.96–45.5), P < 0.0001) was observed in the tRVAD cohort. Compared with concomitant tRVAD support, the delayed tRVAD group did not have a significantly higher risk of adverse events.
Conclusions
In this large single-centre experience, patients undergoing HM3 LVAD requiring tRVAD support had significantly higher risks of adverse clinical outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Advocate Heart Institute, Advocate Christ Medical Center, Oak Lawn, Illinois, USA.
- Aurora St. Luke's Medical Center, Milwaukee, Wisconsin, USA.
Zitieren
APA
Chau, V. Q., Coyle, L., Pedersen, R., Gallagher, C., Graney, N., Kukla, L., Paliga, R., Macaluso, G. P., Pauwaa, S., Cotts, W. G., Pappas, P. S., Tatooles, A. J., & Narang, N. (2025). Analysis of Outcomes in Patients with HeartMate 3 with and Without Right Ventricular Assist Device Support. ESC Heart Failure. https://doi.org/10.1002/ehf2.15353
Vancouver
Chau VQ, Coyle L, Pedersen R, Gallagher C, Graney N, Kukla L, et al. Analysis of Outcomes in Patients with HeartMate 3 with and Without Right Ventricular Assist Device Support. ESC Heart Failure. 2025. doi:10.1002/ehf2.15353
BibTeX
@article{Chau2025,
author = {Chau, Vinh Q and Coyle, Laura and Pedersen, Rachel and Gallagher, Colleen and Graney, Nicole and Kukla, Lisa and Paliga, Robin and Macaluso, Gregory P and Pauwaa, Sunil and Cotts, William G and Pappas, Patroklos S and Tatooles, Antone J and Narang, Nikhil},
title = {Analysis of Outcomes in Patients with HeartMate 3 with and Without Right Ventricular Assist Device Support},
journal = {ESC Heart Failure},
year = {2025},
doi = {10.1002/ehf2.15353}
}
EUVIMED